UCLA Pancreatic Cancer Study and Diabetes Drugs
Recently gathered evidence suggests that some of the most popular diabetic drugs may cause abnormal growth in the pancreas which can lead to pancreatic cancer. Those who have taken certain diabetic drugs to treat type-II diabetes have exhibited unusual activity in the pancreas. The research conducted at the University of California, Los Angeles (UCLA) by Dr. Peter Butler suggested that there may be an increased risk of neuroendocrine tumors.
Part of their discovery was that cell mass within the pancreas had increased by almost 40% among patients taking certain diabetic drugs. There have been some conflicting reports about the effects of these diabetic drugs due to their previously only being studied in animals. The UCLA pancreatic cancer study about diabetic drugs marks the first study to examine changes in the human pancreas.
Head researcher Dr. Peter Butler explained that, ‘There is an increasing appreciation that animal studies do not always predict findings in humans.’ The UCLA pancreatic cancer study looked at the pancreases of 20 organ donors who had passed away with type-II diabetes. Eight of those had been treated with incretin therapy which is the type of diabetic drug currently being scrutinized.
The patients who had been treated with the diabetic drugs including Januvia, Byetta, Victoza, and Actos had noticeably larger pancreases. And this larger size of the pancreas was linked with increased cellular proliferation which is a serious risk factor of pancreatic cancer.
This is likely related to the method that certain GLP-1 (glucagon like peptide -1) diabetic drugs use to suppress the release of glucagon by alpha cells. This can in turn decrease their availability and has been associated with an increased likelihood of precancerous neuroendocrine tumors.
Of the eight donors examined in the UCLA pancreatic cancer study, seven were taking sitagliptin, marketed as
Januvia and one was taking exenatide, marketed as Byetta. Both Januvia and Byetta are currently under further investigation by the Food and Drug administration for their possible link with causing pancreatic cancer, pancreatitis, and thyroid cancer.
The results of the UCLA pancreatic cancer study about diabetic drugs like Januvia and Byetta have produced a much needed wakeup call to the pharmaceutical community about the safety of its drugs. Further research by drug companies is now being demanded by the FDA for certain diabetic drugs.
The scientists who participated in the UCLA pancreatic cancer study suggest that while this was just a small sample size, the concerns about diabetic drugs and pancreatic cancer are very real. They suggest that new approaches and larger groups of living individuals be studied to better understand the diabetic drug pancreatic cancer risk.
Diabetic Drug and Cancer Lawsuit Help
Each of the drugs mentioned in this article are relatively new to the diabetic drug market, and many doctors and clinicians regret their introduction to the market as they believe that some of the more traditional diabetic drug treatments like metformin may be as effective while limiting the diabetic drug cancer risks. The diabetic drugs reviewed in this article that may potentially cause cancer include:
If you or a loved one has taken Januvia, Janumet, Actos, Byetta, Bydureon, or Victoza and developed pancreatitis, pancreatic cancer, bladder or thyroid cancer, you may be entitled to financial compensation through a Diabetic Drug and Cancer Lawsuit. We are here to offer you help with your diabetic drug lawsuit. Please call us today to speak with a Diabetic drug lawyer regarding your options going forward with a diabetic drug lawsuit. All cases are processed on a contingency fee basis which means that you don’t pay anything unless your case is successful.
Call Toll Free 1-800-883-9858 or CLICK HERE -> FREE CASE REVIEW